TY  - GEN
AU  - Lin,Chi
AU  - Verma,Vivek
AU  - Lazenby,Audrey
AU  - Ly,Quan P
AU  - Berim,Lyudmyla D
AU  - Schwarz,James K
AU  - Madiyalakan,Madi
AU  - Nicodemus,Christopher F
AU  - Hollingsworth,Michael A
AU  - Meza,Jane L
AU  - Are,Chandrakanth
AU  - Padussis,James
AU  - Grem,Jean L
TI  - Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma
SN  - 1537-453X
PY  - 2020///0324
KW  - Adenocarcinoma
KW  - diagnostic imaging
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - therapeutic use
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - CA-125 Antigen
KW  - blood
KW  - Camptothecin
KW  - Combined Modality Therapy
KW  - Disease-Free Survival
KW  - Female
KW  - Fluorouracil
KW  - Follow-Up Studies
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Leucovorin
KW  - Magnetic Resonance Imaging
KW  - methods
KW  - Male
KW  - Membrane Proteins
KW  - Middle Aged
KW  - Nelfinavir
KW  - Neoadjuvant Therapy
KW  - Neoplasm Invasiveness
KW  - pathology
KW  - Organoplatinum Compounds
KW  - Pancreatic Neoplasms
KW  - Pancreaticoduodenectomy
KW  - Proportional Hazards Models
KW  - Radiosurgery
KW  - Risk Assessment
KW  - Survival Analysis
KW  - Time Factors
KW  - Tomography, X-Ray Computed
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1097/COC.0000000000000599
ER  -